UCBJF:OTCMKTS
UCB
232,62 USD
arrow_downward
-1,70%(-4,04) 1G
9 ott, 16:00:00 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per UCBJF in corso…
Apertura
236,94 USD
Massimo
236,94 USD
Minimo
232,62 USD
Cap. mercato
39,46 Mld
Vol. medio
137,00
Volume
183,00
Max 52 sett.
345,39 USD
Min 52 sett.
219,60 USD
Beta
0,58
Azioni in circolazione
194,51 Mln
N. di dipendenti
9K
Apertura
236,94 USD
Massimo
236,94 USD
Minimo
232,62 USD
Cap. mercato
39,46 Mld
Vol. medio
137,00
Volume
183,00
Max 52 sett.
345,39 USD
Min 52 sett.
219,60 USD
Beta
0,58
Azioni in circolazione
194,51 Mln
N. di dipendenti
9K
Articoli giornalistici
Da fonti web e partner giornalistici
AD HOC NEWS
·
4 ore fa
UCB stock holds EUR 203.95 in weekend trading
Yahoo! Finance Canada
·
5 ore fa
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?
Financial Times
·
17 ore fa
UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia – Company Announcement
AD HOC NEWS
·
2 giorni fa
UCB stock loses 0.61 percent pre-market to EUR 202.30
Profilo
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Informazioni su UCB